RFK Jr.’s Peptides Push

The FDA is weighing whether to allow broader compounding of certain peptides, as Health Secretary Robert F. Kennedy Jr.’s interest in the substances collides with agency staff concerns, advisory committee recommendations and a growing market for alternative treatments.

What you’ll learn

• How the FDA advisory committee vote could shape peptide compounding policy
• Why agency staff and newly appointed committee members diverged on safety and efficacy questions
• What legal, regulatory and market questions could influence the FDA’s next steps

Why this matters

The peptide debate sits at the intersection of FDA oversight, compounding policy, telehealth demand and alternative health care markets. POLITICO Pro helps health care organizations track how agency decisions, stakeholder pressure and regulatory timelines could shape strategy, risk and policy planning.

Fill out the form to read the full POLITICO Pro analysis.